Litigation prescribed: The Tipline for 24 August 2022
Pharmaceutical companies have played a key role in funding the antitrust bar for several years, but scrutiny of their purportedly anticompetitive conduct took a back seat for a while amid all the Big Tech talk. Drugmakers have faced some hefty setbacks over the last few days, however, with federal judges conclusively refusing to toss claims against Indivior, Gilead Sciences, Cipla, Mylan and Pfizer while Teva Pharmaceuticals was hit with another class action complaint relating to its multiple sclerosis treatment. Today’s Tipline also looks at revisions to a journalism-focused antitrust bill plus a request from DirecTV subscribers to finally move forward as two classes.
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10